Top Story

FDA approves Venclexta-Gazyva regimen for untreated chronic lymphocytic leukemia

FDA approves Venclexta-Gazyva regimen for untreated chronic lymphocytic leukemia
May 15, 2019
FDA News

FDA advisory committee does not support quizartinib for leukemia subtype

May 14, 2019
An FDA panel today did not support approval of quizartinib for the treatment of adults with
Meeting News

Outpatient CAR T-cell therapy possible if done earlier

May 13, 2019
PHILADELPHIA — Chimeric androgen receptor T-cell therapy has a reputation as a game-changing therapy with a hefty price tag. However, as CAR T-cell therapy pioneer…
In the Journals

‘Tremendous racial and ethnic disparity’ observed in access to matched donor stem cells

May 10, 2019
Patients with cancer who need a bone marrow transplant are less likely to find a suitable match if they are of southern-European or non-European descent, according to…
More Headlines »

Ace the Case: A 71-Year-Old Man With Muscle-Invasive Transitional Cell Bladder Cancer 6 Years Previously Presents With Back and Pelvic Pain That Began 2 Months Ago

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of a 71-year-old man with muscle-invasive…
More »
Meeting News

VIDEO: Researchers link mutation to venetoclax resistance in chronic lymphocytic leukemia

December 17, 2018
More »
Resource Centers
Discoveries from ASH Leukemia

Discoveries from ASH Leukemia


Clinical Advances in Cutaneous T-cell Lymphoma: What You Need to Know About a Rare Malignancy

This activity is supported by an educational grant from Kyowa Kirin, Inc.

Cutaneous T-cell lymphoma (CTCL) is a rare and heterogeneous type of T-cell lymphoma that is often challenging to…
More »